Research programme: cytokine-based immunotherapeutics - Precigen Inc
Alternative Names: Research programme: cytokine-based immunotherapeutics - Precigen Inc/ZIOPHARMLatest Information Update: 05 Apr 2023
At a glance
- Originator Intrexon Corporation
- Developer Alaunos Therapeutics; Precigen Inc
- Class Cell therapies; Interleukins; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Graft-versus-host disease